Name: Novo Nordisk Canada is considering competing with affordable Ozempic dupe
Uploaded: 2026-01-07T19:30:06Z
Duration: 29 s
Description: Health Canada approved the company’s submissions for new low-cost weight loss alternatives Plosbrio and Poviztra on Dec. 22.

Toronto Watch

Novo Nordisk Canada is considering competing with affordable Ozempic dupe

Health Canada approved the company’s submissions for new low-cost weight loss alternatives Plosbrio and Poviztra on Dec. 22.

January 07, 2026 at 1:50PM EST